Joann Colman
Adult Health · Gloucester, NJNPI 1457790263
Payments from drug & device makers
Across 319 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$882
- AbbVie$709
- GSK$689
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$321
- Otsuka America Pharmaceutical, Inc.$205
- Sanofi-aventis U.S. LLC$172
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $882 |
| AbbVie | 68 | $709 |
| GSK | 58 | $689 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $321 |
| Otsuka America Pharmaceutical, Inc. | 13 | $205 |
| Sanofi-aventis U.S. LLC | 14 | $172 |
| Amgen | 11 | $170 |
| Almatica Pharma LLC | 11 | $169 |
| Pfizer | 11 | $166 |
| Teva Pharmaceuticals USA, Inc. | 10 | $158 |
| Merck | 12 | $156 |
| Exact Sciences | 6 | $110 |
| Collegium Pharmaceutical, Inc. | 7 | $107 |
| Lundbeck LLC | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 5 | $77 |
| Astellas Pharma US Inc | 4 | $55 |
| Lilly USA, LLC | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Boehringer Ingelheim | 3 | $39 |
| Amarin Pharma, Inc. | 3 | $39 |
| Novo Nordisk | 2 | $34 |
| Biodelivery Sciences International, Inc. | 2 | $23 |
| Corcept Therapeutics | 1 | $17 |
| Novartis | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,524 in reported general payments places this provider in the 90th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 90 | $95,688 |
| EliquisApixaban | 77 | $69,245 |
| OzempicSemaglutide | 64 | $58,632 |
| OxycontinOxycodone Hcl | 55 | $57,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $52,047 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $35,636 |
| JanuviaSitagliptin Phosphate | 30 | $33,173 |
| JardianceEmpagliflozin | 27 | $27,411 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $23,066 |
| MounjaroTirzepatide | 18 | $22,411 |
| EntrestoSacubitril/Valsartan | 11 | $10,292 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,147 |
| Oxycodone Hcl | 195 | $6,471 |
| Varenicline Tartrate | 26 | $5,992 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $882 | $136,822159 claims |
| PfizerEliquis | $166 | $69,24577 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $689 | $66,185107 claims |
| Novo NordiskOzempic | $34 | $58,63264 claims |
| MerckJanuvia | $156 | $33,17330 claims |
| Boehringer IngelheimJardiance | $39 | $27,41127 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $172 | $23,06627 claims |
| Lilly USA, LLCMounjaro | $44 | $22,41118 claims |
| NovartisEntresto | $15 | $10,29211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Gloucester
- June HalperHackensack$458K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.